Show simple item record

dc.contributor.authorJennings, P
dc.contributor.authorAshton-Cleary, S
dc.contributor.authorSugunendran, Suma
dc.contributor.authorHughes, D
dc.contributor.authorIdris, Iskandar
dc.contributor.authorWilmot, Emma
dc.date.accessioned2017-04-25T10:02:53Z
dc.date.available2017-04-25T10:02:53Z
dc.date.issued2017-04
dc.identifier.citationDiabet Med. 2017 Apr 21. doi: 10.1111/dme.13367. [Epub ahead of print]language
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/1061
dc.descriptionAuthor(s) Pre Print Version Only. 12 Month Embargo on Post-Print. No PDFlanguage
dc.description.abstractAIM: In the short term, continuous subcutaneous insulin infusion (CSII) has been associated with improved glycaemic control, reduced hypoglycaemia and improved quality of life (QOL). However, limited data are available on its long-term benefits, particularly in the UK. We aimed to assess the impact of CSII on longer term outcomes. METHOD: Patient-level data were obtained for CSII users at Derby Teaching Hospitals, UK. Patient confidence and satisfaction questionnaires using the Likert scale were used to assess confidence in self-management. Comparative statistics were conducted using Pearson's chi-square and Student's t-tests. RESULTS: Some 258 CSII users were identified (60.1% female, mean age 43.9 ± 13.4 years). Overall, there was significant decrease in HbA1c from 78 mmol/mol (9.3 ± 2.0%) at baseline, to 69 mmol/mol (8.5 ± 1.3%) at 6 months [mean difference (md): -0.64; 95% confidence interval (95% CI): -0.91 to -0.37; P < 0.0001]; which was sustained at 6 years of follow-up (HbA1c : 66 mmol/mol, 8.2 ± 1.3%; md: -1.07%; 95% CI: -1.45 to -0.69; P < 0.0001). One hundred and twenty-one patients (47%) responded to the survey, of whom 95 (78.5%) reported a reduction in the frequency of hypoglycaemia; 102 (84.3%) were satisfied with the quality of care received in the insulin pump service. CONCLUSION: CSII therapy led to a sustained long-term improvement in glycaemic control in addition to a reduction in self-reported hypoglycaemia.language
dc.language.isoenlanguage
dc.subjectSubcutaneous Insulin Infusionlanguage
dc.subjectGlucoselanguage
dc.titleContinuous subcutaneous insulin infusion (CSII) therapy at Derby Teaching Hospitals: sustained benefits in glucose control.language
dc.typeArticlelanguage


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record